Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research9

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research9

FiltersClear all

Status

Recruiting5
Active, not recruiting2
Completed1
Terminated1

Study type

Interventional8
Observational1

Phase

Phase 23
Phase 33
Phase 2/31
Not applicable1
Not reported1

Investigator

Sonal Kumar4
Robert S. Brown3
Adam Buckholz1
Danielle Brandman1

Department

Medicine9

Condition

Fibrosis9
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50

Intervention type

Drug6
Biological2
Dietary supplement1
Other1

Sponsor type

Industry6
Other academic1
NIH1
WCM (investigator-initiated)1

Start date

Has results posted1

Fibrosis×Clear all

Showing 1–9 of 9 studiesSort:

Active, not recruitingInterventional · Phase 3NCT04849728 ↗
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Sonal KumarPI
Intervention
Drug: IVA337 · Drug: Placebo
Dates
Aug 2021 – Sep 2026

FiltersClear all

Status

Recruiting5
Active, not recruiting2
Completed1
Terminated1

Study type

Interventional8
Observational1

Phase

Phase 23
Phase 33
Phase 2/31
Not applicable1
Not reported1

Investigator

Sonal Kumar4
Robert S. Brown3
Adam Buckholz1
Danielle Brandman1

Department

Medicine9

Condition

Fibrosis9
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50

Intervention type

Drug6
Biological2
Dietary supplement1
Other1

Sponsor type

Industry6
Other academic1
NIH1
WCM (investigator-initiated)1

Start date

Has results posted1

Fibrosis×Clear all

Showing 1–9 of 9 studiesSort:

Active, not recruitingInterventional · Phase 3NCT04849728 ↗
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Sonal KumarPI
Intervention
Drug: IVA337 · Drug: Placebo
Dates
Aug 2021 – Sep 2026

Show fewer

Multiple Myeloma32
Neoplasms32
Colitis, Ulcerative29
Atrial Fibrillation27
Carcinoma, Non-Small-Cell Lung27
Crohn Disease27
Recurrence27
COVID-1926
Myelodysplastic Syndromes26
Parkinson Disease24
Neoplasm Metastasis23
Obesity23
Colorectal Neoplasms19
HIV Infections19
Hematologic Neoplasms19
Cardiovascular Diseases18
Depression18
Non-alcoholic Fatty Liver Disease16
Overweight15
Lung Neoplasms14
Melanoma14
Cognitive Dysfunction13
Idiopathic Pulmonary Fibrosis13
Inflammatory Bowel Diseases13
Alzheimer Disease12
Leukemia12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Coronary Artery Disease11
Hypertension11
Hypertension, Pulmonary11
Lung Diseases, Interstitial11
Myeloproliferative Disorders11
Pulmonary Arterial Hypertension11
Stroke11
Chronic Pain10
Hemophilia A10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Large B-Cell, Diffuse10
Urinary Bladder Neoplasms10
Burkitt Lymphoma9
Liver Diseases9
Carcinoma, Renal Cell8

Sponsor

Inventiva S.A.

NASH - Nonalcoholic Steatohepatitis

Active, not recruitingObservationalNCT05740358 ↗

Liver Cirrhosis Network Cohort Study

Robert S. BrownPI

Dates: Nov 2022 – Oct 2030 (est.)
Sponsor: National Institutes of Health

CirrhosisCirrhosis, LiverCirrhosis Early+9 more

RecruitingInterventional · Phase 2NCT05832229 ↗

Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study

Robert S. BrownPI

Intervention: Drug: Rosuvastatin
Dates: Dec 2023 – Aug 2029 (est.)
Sponsor: National Institute of Diabetes & Digestive & Kidney Diseases

CirrhosisCirrhosis, LiverCirrhosis Early+5 more

RecruitingInterventional · Phase 3NCT06318169 ↗

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Sonal KumarPI

Intervention: Biological: Pegozafermin · Other: Placebo
Dates: Mar 2024 – Feb 2029 (est.)
Sponsor: 89Bio INC

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

RecruitingInterventional · Phase 3NCT06419374 ↗

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)

Sonal KumarPI

Intervention: Biological: Pegozafermin · Drug: Placebo
Dates: May 2024 – Jun 2028 (est.)
Sponsor: 89Bio INC

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

RecruitingInterventional · Not applicableNCT07046429 ↗

Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) Trial

Adam BuckholzPI

Intervention: Dietary supplement: Melatonin tablet 3 mg once daily · Dietary supplement: Thiamine
Dates: Aug 2025 – Dec 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Hepatic EncephalopathyCovert Hepatic EncephalopathyCirrhosis+1 more

RecruitingInterventional · Phase 2NCT07335601 ↗

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies

Danielle BrandmanPI

Intervention: Drug: Resmetirom · Drug: Placebo
Dates: Dec 2025 – Aug 2028 (est.)
Sponsor: Madrigal Pharmaceuticals, Inc.

MASH - Metabolic Dysfunction-Associated Steatohepatitis

TerminatedInterventional · Phase 2/3NCT04365868 ↗

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Sonal KumarPI

Intervention: Drug: belapectin · Drug: Placebo
Dates: Jun 2020 – Mar 2025· Results posted
Sponsor: Galectin Therapeutics

Prevention of Esophageal VaricesNASH - Nonalcoholic SteatohepatitisCirrhosis

CompletedInterventional · Phase 2NCT05309200 ↗

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)

Robert S. BrownPI

Intervention: Drug: OCE-205 · Drug: Placebo
Dates: Apr 2022 – Sep 2023
Sponsor: Ocelot Bio, Inc.

CirrhosisAscitesHepatorenal Syndrome+1 more